The National Institute on Aging, a division of the National Institutes of Health, is awarding a $1.76 million, one-year grant to support a Phase 1 clinical trial investigating oral Jotrol as a potential treatment of early stage Alzheimer’s disease. The study is to be called “Safety and Pharmacokinetics of JOTROL for Alzheimer’s Disease.” Further information, including an…
The Alzheimer’s Association has been chosen to lead a national public health effort aimed at lowering the risk of cognitive decline and dementia. The organization was selected by the Centers for Disease Control and Prevention (CDC) as a Building Our Largest Dementia (BOLD) Public Health Center of Excellence (PHCOE) for dementia risk reduction. To fund…
Treatment with sumifilam significantly lowered the levels of multiple biomarkers of disease activity, neurodegeneration, and inflammation in people with mild-to-moderate Alzheimer’s after 28 days of treatment, according to final data from a Phase 2b trial. Sumifilam, Cassava Sciences’ lead investigational candidate for Alzheimer’s disease, also was found to be safe and well-tolerated, and to improve…
A specific form of the tau protein, called phosphorylated-tau-217 or p-tau217, may function as a blood biomarker of Alzheimer’s disease, allow the development of blood tests to accurately diagnose the disease at earlier stages. These are the findings of three studies presented during the recent Alzheimer’s Association International Conference (AAIC) 2020. The brains of those with Alzheimer’s disease show…
Events are underway to mark World Alzheimer’s Month, observed every September to raise global awareness about the disease and challenge the stigma regarding dementia. September 21 has been designated World Alzheimer’s Day. Approximately 44 million people worldwide have Alzheimer’s disease, the most common form of dementia and an irreversible progressive neurological disorder. In the U.S., roughly 5.5 million…
Axsome Therapeutics announced plan to soon open a Phase 3 clinical trial of AXS-05, its investigational oral treatment for Alzheimer’s disease-related agitation, after U.S. Food and Drug Administration (FDA) officials confirmed an earlier study was pivotal. Results from this new efficacy trial, to open before year’s end, are expected to support a new drug application (NDA) seeking…
The first three patients have been dosed in a Phase 2a clinical trial investigating Annovis Bio‘s lead compound ANVS401 as a treatment for people with early Alzheimer’s and Parkinson’s diseases, the company said. The trial (NCT04524351) will recruit up to 68 participants at 15 sites scattered across the U.S. Thus far, only the sites in Florida…
To help accelerate the development of treatments for Alzheimer’s disease, the Alzheimer’s Association’s Part the Cloud research grant program is investing $24 million in clinical trials investigating 16 potential therapies. Scientists from around the world will use the funds to conduct Phase 1 and 2 trials testing a variety of experimental medications and devices. The studies…
A new non-invasive technique that can temporarily “open” the blood-brain barrier may make it easier for promising therapies to enter the brain of people with Alzheimer’s disease, a study reports. The study, “Noninvasive hippocampal blood−brain barrier opening in Alzheimer’s disease with focused ultrasound,” was published in the journal Proceedings of the National Academy of Sciences. …
People in Australia with Alzheimer’s disease who have finished five years of treatment with Anavex 2-73 (blarcamesine) in Phase 2 clinical trials may continue to use Anavex Life Sciences‘ investigational oral therapy at their doctor’s request. Under a special access scheme, the Therapeutic Goods Administration (TGA) — a part of the Australian Government Department of Health — allowed for compassionate use based…
